Valuation: ProPhase Labs, Inc.

Market Cap 491K 424K 396K 364K 684K 46.69M 695K 4.65M 1.82M 23.4M 1.84M 1.8M 77.36M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 9.02M 7.8M 7.29M 6.68M 12.57M 858M 12.77M 85.47M 33.55M 430M 33.87M 33.13M 1.42B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-13.79%
1 week+199.27%
Current month+199.27%
1 month+39.20%
3 months+4.17%
6 months-16.67%
Current year-72.07%
1 week 0.03
Extreme 0.0301
0.14
1 month 0.03
Extreme 0.0301
0.14
Current year 0.03
Extreme 0.0301
0.47
1 year 0.03
Extreme 0.0301
6.66
3 years 0.03
Extreme 0.0301
74.8
5 years 0.03
Extreme 0.0301
152.5
10 years 0.03
Extreme 0.0301
160.4
Manager TitleAgeSince
Chief Executive Officer 67 18/06/2009
Director of Finance/CFO 66 05/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 18/06/2009
Director/Board Member 70 31/05/2009
Director/Board Member 56 19/06/2025
Date Insider Type Main position Quantity % Market Cap.
09/09/25 Free

Chief Executive Officer

500,000 1.2036%
17/02/25 Free

Chief Operating Officer

500,000 1.6737%
14/02/25 Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-13.79%+199.27%-96.17%-99.82% 491K
+21.37%+20.29%+128.31%+531.32% 46.26B
+0.83%+3.22%+22.78%+48.87% 25.88B
+0.04%+1.78%-20.11%-34.65% 7.76B
+6.20%+13.49%+37.80%+114.41% 5.69B
+0.19%+1.39%+20.23%+62.71% 3.39B
+10.76%+18.38%-27.25%+1,052.17% 2.3B
+6.49%+8.37%+187.67%+4.87% 2.13B
+11.67%+10.56%+30.24%+20.78% 2.02B
+3.35%+4.36%-5.60%-56.72% 1.99B
Average +4.71%+7.80%+27.79%+164.39% 9.74B
Weighted average by Cap. +11.44%+12.13%+72.25%+295.55%

Financials

2024 2025
Net sales 6.77M 5.86M 5.47M 5.02M 9.44M 644M 9.59M 64.16M 25.18M 323M 25.42M 24.87M 1.07B 4.34M 3.76M 3.51M 3.22M 6.06M 414M 6.15M 41.18M 16.16M 207M 16.32M 15.96M 685M
Net income -53.36M -46.16M -43.11M -39.54M -74.38M -5.08B -75.56M -506M -199M -2.55B -200M -196M -8.42B -14.74M -12.75M -11.91M -10.92M -20.55M -1.4B -20.87M -140M -54.84M -703M -55.36M -54.15M -2.33B
Net Debt 23.9M 20.67M 19.3M 17.71M 33.3M 2.27B 33.83M 226M 88.88M 1.14B 89.73M 87.77M 3.77B 8.53M 7.38M 6.89M 6.32M 11.89M 812M 12.07M 80.82M 31.72M 407M 32.02M 31.32M 1.34B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
07/08/26 US$0.0350 -23.91% 525,359
06/08/26 US$0.0460 +5.07% 140,017
05/08/26 US$0.0438 -8.79% 132,081
04/08/26 US$0.0480 +15.80% 18,898
03/08/26 US$0.0415 -0.76% 20,473

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock